Clinical Trials Logo
  1. Home
  2. Myasthenia Gravis, Generalized
  3. NCT05868837

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) — REFINE  

Myasthenia Gravis, Generalized Clinical Trial

Official title:
Single-cell Deep Phenotyping of B Lymphocytes to Personalize Immunotherapy in Patients With Myasthenia Gravis: Clinical Trial to Evaluate the Efficacy and Safety of Rituximab in Generalized AChR-antibody Positive Myasthenia Gravis

Clinical Trial Summary

The primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: - Allow faster and greater corticosteroid tapering - Reduce the frequency of exacerbations - Improve quality of life - Offer an acceptable safety and tolerability profile.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05868837
Study type Interventional
Source Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Raffaele Iorio
Phone +393347185128
Email raffaele.iorio@policlinicogemelli.it
Status Recruiting
Phase Phase 3
Start date February 28, 2022
Completion date July 31, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT02565576 - Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis Phase 2
Completed NCT04115293 - Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis Phase 3
Recruiting NCT05737160 - Study of Telitacicept in Generalized Myasthenia Gravis Phase 3
Recruiting NCT04224506 - A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
Recruiting NCT04431895 - Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study Early Phase 1
Recruiting NCT05067348 - Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis Phase 2
Withdrawn NCT03165435 - A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis Phase 2/Phase 3
Recruiting NCT05214612 - Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Recruiting NCT06282159 - A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) Phase 2
Recruiting NCT04146051 - Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) Phase 2
Completed NCT03759366 - A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) Phase 3
Completed NCT02473952 - A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis Phase 2
Completed NCT00683969 - A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis Phase 3
Completed NCT03304054 - Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Phase 3
Recruiting NCT05716035 - Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis Phase 2/Phase 3